Comparative Analysis of Antimicrobial Resistance Patterns among Uropathogenic Escherichia coli and Klebsiella pneumoniae Isolates from Referral Hospitals in Chad and Cameroon

The Invisible War in Your Bladder

Imagine your body is a bustling city, and the urinary tract is a busy highway system. Usually, this highway is clean and empty, but sometimes, tiny invaders called bacteria try to crash the party. When they do, they cause a Urinary Tract Infection (UTI), which feels like a painful traffic jam in your lower belly. The city's defense force is our immune system, but these bacteria are clever; they can wear "camouflage" called antimicrobial resistance. Think of this resistance like a superhero shield that makes the bacteria invisible to the weapons we use to fight them: antibiotics.

For a long time, doctors have had a toolbox full of different antibiotics to clear these infections. But lately, the bacteria have been learning how to break the tools. This is a global problem, but it's especially tricky in places where doctors might not have the latest maps (surveillance data) to know which weapons still work. This paper dives into two specific countries in Central Africa—Chad and Cameroon—to see if the bacteria causing these infections are wearing the same "shields" or if they have different tricks up their sleeves. The goal is simple: figure out which antibiotics are still strong enough to win the battle and which ones have become useless.

The Battle Report: Chad vs. Cameroon

This study acts like a detective story, comparing two major hospitals: the National Reference University Hospital Center (CHU-RN) in N'Djamena, Chad, and the Military Region Hospital N°1 (HMR1) in Yaoundé, Cameroon. The researchers looked at urine samples from 550 patients (300 from Chad, 250 from Cameroon) collected between February and July 2025. They were hunting for two specific "villains": Escherichia coli (or E. coli) and Klebsiella pneumoniae. These are the two most common bacteria that cause UTIs.

Who was fighting?
The "armies" of patients looked different at each hospital. At the Chad hospital, most of the patients were men (66%), while at the Cameroon hospital, most were women (64.4%). This makes sense because women are generally more prone to UTIs due to their anatomy, but the Chad hospital saw more men, perhaps because they were there for specific urological issues. The most common age group for these infections in both places was the 61–70 year olds, likely because older bodies have a harder time fighting off these invaders.

The Villains Revealed
When the scientists grew the bacteria from the urine samples, they found that E. coli was the big boss in both places, followed closely by K. pneumoniae.

• In Chad, E. coli showed up in 19.3% of all samples, and K. pneumoniae in 6.7%.
• In Cameroon, E. coli appeared in 10.8% of samples, and K. pneumoniae in 6.0%.

The Weapons Test
The real drama happened when the researchers tested the bacteria against various antibiotics to see which ones could still punch through their shields. They used a method called "disk diffusion," which is like placing little paper circles soaked in medicine on a plate of bacteria to see if the bacteria stop growing around them.

Here is what they found:

• The Broken Swords (High Resistance):
  The bacteria were incredibly tough against the most common, older antibiotics.

  • Amoxicillin: This was a total failure. In Chad, 70.5% to 95.0% of the bacteria ignored it. In Cameroon, the numbers were just as scary, with 85% to 95% of the bacteria resisting it.
  • Amoxicillin-Clavulanic Acid: This is a stronger version of the first one, but it was also struggling. Resistance ranged from 52.0% to 75.0% across both hospitals.
  • Fluoroquinolones (Ciprofloxacin and Levofloxacin): These are popular drugs, but the bacteria in Chad had learned to dodge them very well. In Chad, 65.5% of E. coli was resistant to ciprofloxacin, while K. pneumoniae showed a resistance rate of 22.41%. In Cameroon, the resistance was lower but still present (37.0% and 22.2% for E. coli).

• The Last Line of Defense (Low Resistance):
  There was some good news. The "super-weapons" known as Carbapenems (specifically Imipenem) were still working.

  • In Chad, only 7.4% of E. coli and 8.62% of K. pneumoniae could resist Imipenem.
  • In Cameroon, the numbers were slightly higher but still low: 18.51% for E. coli and 15.51% for K. pneumoniae.
    This suggests that Imipenem is still a reliable shield-breaker, though we have to be careful not to overuse it or the bacteria might learn to resist it too.

• The Middle Ground:
  Drugs like Gentamicin and Nitrofurantoin showed mixed results. In Chad, E. coli was very sensitive to Gentamicin (only 7.4% resistance), but in Cameroon, resistance was higher (22.22%). This shows that even neighboring countries can have very different bacterial "personalities."

The Big Difference
The study found that the two hospitals were not fighting the exact same war. The resistance patterns were significantly different (a statistical difference with a p-value of less than 0.001). For example, E. coli in Chad was much harder to kill with fluoroquinolones than the E. coli in Cameroon. This means that a doctor in Chad cannot simply copy the treatment plan from a doctor in Cameroon; they need their own local map of which drugs work.

The Takeaway

The main finding is clear: the bacteria causing urinary infections in both Chad and Cameroon have built massive walls against the most common antibiotics, especially amoxicillin and fluoroquinolones. However, the specific "blueprints" for these walls differ between the two countries.

The paper suggests that while we are losing the battle with older drugs, the newer "last-resort" antibiotics (like Imipenem) are still effective. But this is a warning, not a victory lap. The authors argue that if we keep using these last-resort drugs without a plan, the bacteria will eventually learn to resist them too. They conclude that we need constant, local surveillance to track these changes and strict rules on how doctors prescribe antibiotics, ensuring that we don't accidentally train the bacteria to become invincible. The battle for our urinary highways is ongoing, and the rules of engagement need to change every day.